FMP

FMP

Enter

VIVO - Meridian Bioscience,...

photo-url-https://images.financialmodelingprep.com/symbol/VIVO.png

Meridian Bioscience, Inc.

VIVO

NASDAQ

Inactive Equity

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

33.97 USD

0 (0%)

Latest vivo News

Investors Business Daily

Nov 17, 2022

Medical Devices Stock Pumps Up Buy Point With New Innovations

After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new buy point. The post Medical Devices Stock Pumps Up Buy Point With New Innovations appeared first on Investor's Business Daily.

Read More

The Motley Fool

Oct 7, 2022

4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire

This quartet of stocks has plenty of growth ahead and is already profitable.

Read More

Zacks Investment Research

Jul 29, 2022

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More

InvestorPlace

Jul 7, 2022

Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement

VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The post Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement appeared first on InvestorPlace.

Read More

Market Watch

Jul 7, 2022

Meridian Bioscience agrees to $1.5 billion buyout by SD Biosensor, SJL Partners

Meridian Bioscience Inc. VIVO, +7.02% announced an agreement Thursday to be acquired by a consortium of South Korea-based SD Biosensor Inc. 137310, +2.08% and private equity firm SJL Partners LLC in a cash deal valued at $1.53 billion. Under terms of the deal, Meridian shareholders will receive $34.00 in cash for each Meridian share they own, representing a 1.3% premium to Wednesday's closing price of $33.55.

Read More

Seeking Alpha

Jul 5, 2022

Meridian Bioscience Is Not Your Average Life Science Company

100% technical buy signals. 8 new highs and up 15.79% in the last month.

Read More

Zacks Investment Research

Jun 20, 2022

Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?

Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Read More

PRNewsWire

May 23, 2022

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference.

Read More

The Motley Fool

May 12, 2022

3 Red-Hot Stocks That Could Continue to Beat the Market

These three companies are among the few that have seen their shares rise so far this year.

Read More

Benzinga

May 6, 2022

Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $99.54 million. Revenues from the life science division grew 32% Y/Y to $70.1 million.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep